84 results about "Non steroidal" patented technology

The application provides a method for analyzing the synergistic mechanism of hepatotoxicity and nephrotoxicity of non-steroidal anti-inflammatory drugs. The method comprises the following steps: preliminary toxicity prediction of NSAIDs and collection of toxicity target points, collection of liver and kidney disease target points, then cross and screening of the target points to obtain core target points and common core target points of NSAIDs induced liver and kidney diseases, and then constructing a protein interaction network of the common core target points; enrichment analysis of the common core target points to obtain the common action pathway of NSAIDs induced liver and kidney diseases; finally, further screening of the common core target points to obtain the key target points of NSAIDs induced liver and kidney diseases, and verification by using molecular docking technology. Compared with the traditional method, the advantages of the method are: first, the method does not depend on large-scale patient clinical data and a large number of animal or cell experiments, avoiding the ethical controversy in animal experiments and human experiments; second, the method can identify the potential cross-pathway and synergistic toxicity mechanism when a compound triggers multiple diseases, which is helpful for more comprehensive evaluation of the toxicity risk of NSAIDs.

This specification describes softgel capsules comprising a filler material and a shell composition. The filler material may contain alkali metal salts of NSAIDs and acetaminophen, but may not contain povidone. The shell composition may contain a film-forming material. The softgel capsules may have at least about 99% assay stability at room temperature after 12 months.

The present invention provides a tegoprazan sugar acid salt and a preparation method therefor, the salt being pharmaceutically usable for gastroesophageal disease, gastroesophageal reflux disease, gastritis, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcer, non-erosive reflux disease (NERD) and the like. The tegoprazan sugar acid salt of the present invention has excellent water solubility and stability of tegoprazan, and thus can be particularly useful as a pharmaceutical injection preparation.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to a patch (1) for the topical treatment of sinusitis in a person to be treated, the patch (1) comprising at least one active section (2) with at least one active ingredient and at least one adhesive section (3), wherein the patch (1) is designed to be at least partially, preferably completely, occlusive in the at least one active section (2) and / or in the at least one adhesive section (3), wherein it is provided according to the invention that the at least one active section (2) contains a therapeutically effective amount of a non-steroidal anti-inflammatory drug and / or its physiologically compatible compounds / salts and / or physiologically compatible chemical derivatives as the at least one active ingredient, and that the patch (1) has a shape that is adapted to the anatomical conditions of the application site, wherein the application site is in the face in the area of ​​at least one of the paranasal sinuses,preferably located in the area of ​​the cheek of the person to be treated, in order to enable targeted percutaneous treatment of the sinusitis.

The present invention discloses a method for alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from the group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP-1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP-1 receptor co-agonists, and combinations thereof, by administering a composition containing colostrum product, bovine colostrum, or combinations thereof to a subject. The present invention discloses compositions and kits related to alleviating gastrointestinal side effects resulting from the administration of pharmaceutical agents selected from a group including non-steroidal anti-inflammatory drugs (NSAIDs), glucagon-like peptide-1 (GLP -1) receptor agonists, gastric inhibitory polypeptide (GIP) receptor agonists, dual GIP / GLP -1 receptor co-agonists, and combinations thereof. This method provides a novel approach to mitigate gastrointestinal side effects associated with the use of these pharmaceutical agents, enhancing patient comfort and compliance during treatment.

Methods are described for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to the cancer patient, effective in reducing the patient's NLR. The methods include administering a nonsteroidal GRA and cancer therapy to the cancer patient, effective in reducing the patient's NLR and enhancing the cancer patient's treatment. The GRA may be administered orally. The nonsteroidal GRA may be a nonsteroidal compound comprising a fused azadecalin heteroarylketone structure (e.g., relacorylant) or a fused octahydro azadecalin structure (e.g., exicorylant).Cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. These methods can enhance cancer treatment, improve the prognosis of cancer patients, improve cancer patient survival, and provide beneficial clinical effects and advantages for the patient.

Disclosed herein are novel IEX-NSAID complexes comprising a nonsteroidal anti-inflammatory drug (NSAID) or a salt thereof bound to an ion-exchange (IEX) resin, as well as liquid dosage forms thereof, and their use for treating, ameliorating, preventing, or reducing the severity of numerous conditions, or their symptoms, for with NSAID are the prescribed treatment. Also disclosed herein are methods for making the aforementioned IEX-NSAID complexes, and liquid dosage forms thereof.

The present invention relates to the medical device and ophthalmological industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural neuroprotective components. The invention describes an iontophoretic delivery of cannabinoid-based formulations designed for ophthalmic conditions, that comprise pharmaceutically acceptable charged vehicles, including but not limited to cationic surfactants, cyclodextrins, nanoparticles and microspheres, emulsions or liposomes, with control the size distribution, potential, osmolality and pH. In a further embodiment of the invention, the intraocular composition proposed further comprises one or more synergistic agents, including but not limited to neuropeptides, exosomes, mitochondrial-derived peptides, complement inhibitors, senolytics, autophagy enhancers, antioxidants, saffron, and non-steroidal anti-inflammatory pharmaceutical drugs with pharmaceutically acceptable charged vehicle.

There is provided a compound of formula I, X-Y (I) wherein: Y comprises a peptide fragment of formula IV, [Ala] m-[Lys-V] n-Lys-V (IV) wherein m represents 0 or 1, n represents the integer 0, 1, 2, 3 or 4, and each V independently represents a sequence of 2 to 4 amino acids wherein the amino acids are selected from one or more of the group consisting of Lys, Pro, Hyp, diHyp, Thr, pThr, DOPA, Tyr and Ser; and X represents at least one optional substituent selected from the group consisting of: (i) a lipid selected from the group consisting of vitamin A, vitamin E, cholesterol and fatty acids comprising one or more carboxylic acid groups, 1 to 50 carbons and / or one or more cyclic rings, said lipids being linear or branched, saturated or unsaturated with between 1 and 10 carbon-carbon double bonds and / or substituted with between 1 and 10-OH groups, or a derivative of any of these lipids; and / or (ii) a non-steroidal anti-inflammatory agent, which compounds may be used in medicine, including as pharmaceutical excipients, adhesives and film-forming materials, and / or may be used in the treatment of conditions characterized by inflammation, including wounds, burns and mucosal disorders such as skin diseases, oral diseases, gynecological diseases and IBD.

Drug-loaded microspheres containing both a steroidal anti-inflammatory drug and a non-steroidal anti-inflammatory drug and injectable formulations containing the microspheres for sustained release of both drugs are disclosed. Methods of making such drug-loaded microspheres, formulations, and use of them for treating pains and inflammations, especially those caused by rheumatoid arthritis or osteoarthritis using such microspheres and formulations are also described.

The invention relates to a method for purifying a non-steroidal GnRH agonist polypeptide, in particular to a method, a system and a product for preparing water-soluble high-purity delorelin acetate. According to the invention, a raw material medicine existing in a high acetate form is obtained through preparative-grade reversed-phase chromatography purification, ion conversion on a column and optimization of salt conversion and freeze-drying pretreatment. The HPLC purity of the product is greater than or equal to 98.5%, the acetic acid content is about 13.9%-14.7% (w / w), the solubility in pure water is greater than or equal to 120 mg / mL, and the product is kept clear for 24 hours; the retention time is consistent with that of a commercial reference substance. And compared with a contrast, the method has the advantages that the high-purity fraction yield is obviously improved, impurities and non-target pair ion residues are reduced, and the method is suitable for industrial amplification and preparation development.

Provided herein are compositions suitable for treating chemically induced eye damage comprising (a) a nonsteroidal anti-inflammatory drug (NSAID), (b) a histone deacetylase (HDAC) inhibitor and (c) an angiotensin converting enzyme (ACE) inhibitor and, optionally, (d) a water-soluble vitamin. Methods of using provided compositions to treat ocular toxicity and corneal damage following exposure to chemical agents (e.g., mustard gas) are also provided.

The invention discloses a method for preparing a niflufenamic acid crystal form through melt crystallization, and relates to a preparation method of a medicine crystal form. The crystal form A prepared by the invention has characteristic peaks at 9.8 + / -0.2 degrees, 12.6 + / -0.2 degrees, 16.7 + / -0.2 degrees, 23.4 + / -0.2 degrees and 25.6 + / -0.2 degrees according to X-ray powder diffraction 2 theta. The crystal form A is good in thermal stability, the quality is basically kept stable below 200 DEG C, and the crystal form A can stably exist for more than four weeks under the condition of 40 DEG C / 75% RH; meanwhile, the hygroscopicity is low, the transportation and long-term storage of the product are facilitated, the solubility is good, the solubility in an ethanol solution at 25 DEG C for 24 hours can reach about 0.013455 mg / mL, and the absorption of the medicine in a human body can be promoted. The crystal form of niflufenamic acid (NFA) is a non-steroidal anti-inflammatory drug and has pharmacological activities of resisting inflammation, easing pain and relieving fever.

The invention discloses puerarin-polypeptide co-assembled nano hydrogel, and belongs to the technical field of biological medicines. In order to solve the problems that puerarin is poor in water solubility and stability and diabetic wounds are difficult to heal, the hydrogel comprises self-assembled polypeptide and puerarin with the mass ratio of 1: (0.5-4), the molecular formula of the self-assembled polypeptide is R-GDFDFDY, D represents amino acid in a D configuration, and R is a non-steroidal anti-inflammatory drug. The self-assembled polypeptide and the puerarin are co-assembled to form the nano hydrogel, so that the solubility and the stability of the puerarin are improved, and the nano hydrogel can be used for preparing the diabetes wound healing medicine.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The present invention discloses an amino acid derivative containing a non-steroidal anti-inflammatory drug structure and a preparation method and application thereof. The structural formula of the derivative is as represented by formula I. The novel compound has a broad-spectrum anti-tumor effect, can prolong the survival period of tumor patients, and improve the quality of life of tumor patients.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The application discloses a polypeptide pka15 with immunoregulation efficacy and application thereof. The polypeptide pka15 provided by the application has immunoregulation efficacy, can significantly reduce the number of macrophages and neutrophils at an inflammation site, and can be used for preparing a medicine for relieving and / or treating autoimmune diseases and allergic diseases caused by inflammation. Meanwhile, the polypeptide pka15 can significantly improve the symptoms of IBD, has the efficacy of improving damage to a digestive tract mucosa, can be used for preparing a medicine for relieving and / or treating inflammatory bowel disease and a medicine for protecting and / or repairing damage to the digestive tract mucosa, can be synthesized by a biological or chemical method, is easy to be prepared in a large amount, has simple synthesis, can be prepared into a polypeptide preparation, is convenient for subsequent clinical application and popularization, has no toxic side effects, has better safety as compared with existing glucocorticoid and non-steroidal immunoregulation medicines, and has low medicine cost and good curative effect.

The invention relates to the technical field of medicines, and particularly discloses application of 9-anthraformic acid in preparation of a non-addictive peripheral analgesic medicine. It is proved for the first time that 9-anthracene formic acid has a remarkable analgesic effect and can effectively relieve inflammatory pain, the action target is a peripheral part, central side effects such as addiction and respiratory depression of traditional opioid analgesic are avoided, gastrointestinal injury, cardiovascular risk and curative effect capping effect of non-steroidal anti-inflammatory drugs are also overcome, and the 9-anthracene formic acid can be applied to preparation of anti-inflammatory drugs. Animal experiments prove that the analgesic effect of the compound is comparable with that of classical opioid drug morphine, and a brand new candidate drug and an application direction are provided for developing novel non-addiction analgesic drugs.

The invention belongs to the field of analytical chemistry, and particularly relates to a method for separating and determining a key starting material and related impurities of a non-steroidal anti-inflammatory drug by an HPLC (High Performance Liquid Chromatography) method, gradient elution is carried out by adopting a chromatographic column taking octadecylsilane chemically bonded silica as a filler, a 0.1% phosphoric acid solution as a mobile phase A and acetonitrile as a mobile phase B, and detection is carried out in a detector. The non-steroidal anti-inflammatory drug key starting material and related impurities can be effectively separated, and the method has the advantages of high sensitivity and separation degree, good repeatability and durability, simple operation and stable and reliable result, and is of great significance for realizing the quality control of the non-steroidal anti-inflammatory drug.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The use of AKR1C3 enzyme-activated DNA alkylating agent prodrug compounds containing aziridine structures, as well as their salts, esters, solvates, and isotopic isomers, in combination with anti-allergy drugs / nonsteroidal analgesics for the treatment of cancer and tumor patients; and the use of AKR1C3 enzyme-activated DNA alkylating agent prodrug compounds containing aziridine structures, as well as their salts, esters, solvates, and isotopic isomers, in combination with anti-allergy drugs / nonsteroidal analgesics in the preparation of drugs for the treatment of cancer and tumors.

The invention relates to the technical field of environmental medicine and reproductive toxicology, in particular to application of aspirin in prevention and / or treatment of male reproductive injury caused by rare earth elements. The invention also relates to a method for improving sperm quality reduction caused by rare earth element exposure. The method comprises the step of administering an effective dose of aspirin or a pharmaceutically acceptable salt thereof to an individual in need thereof. The invention also relates to a pharmaceutical composition for preventing and / or treating male reproductive injury caused by rare earth elements. The cognitive limitation of a traditional oxidative stress mechanism is broken through, a new mechanism of rare earth reproductive toxicity is disclosed from a new perspective of testis immune microenvironment for the first time, and an intervention scheme aiming at the new mechanism is provided. According to the invention, the aspirin is creatively used for solving the novel public health problem of low-dose long-term exposure of rare earth elements for the first time, and a new application field is developed for non-steroidal anti-inflammatory drugs.

The invention provides a drug-drug salt of ribociclib (English name Ribociclib) and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, a crystal of the drug-drug salt, a preparation method of the crystal, a pharmaceutical composition containing the crystal and application of the pharmaceutical composition. In the drug-drug salt, ribociclib is connected with a non-steroidal anti-inflammatory drug containing a carboxylic acid group through an intermolecular ionic bond. The drug-drug salt obtained by the invention can realize the synergistic interaction of ribociclib and a non-steroidal anti-inflammatory drug containing a carboxylic acid group, improves the anti-tumor activity of ribociclib, can improve the solubility of ribociclib, and improves the physical stability and bioavailability.

Methods for increasing local blood circulation in soft tissue, treating musculoskeletal tissue, and treating soft tissue of a subject are described. Continuous, non-pulsed ultrasound energy can be applied to a target tissue region, such as with a wearable ultrasound transducer. The ultrasound energy can be delivered at an intensity suitable for sustained application for at least 60 minutes. A statistically significant increase in local blood circulation can be achieved within 10 minutes of initiating application, occurring before a statistically significant increase in tissue temperature. In some embodiments, a topical non-steroidal anti-inflammatory drug (NSAID) is applied to the target region during ultrasound application. In some embodiments, local blood circulation is monitored using laser Doppler flowmetry until a statistically significant increase in perfusion units is detected. The increase in local blood circulation can be effective to alleviate pain and accelerate recovery from a soft tissue injury.

The disclosure provides methods and devices for the treating or preventing a benign uterine disorder in a female mammalian subject. The methods comprise administering a non-steroidal angiogenesis inhibitor. Such methods and devices are particularly useful for treating women suffering from adenomyosis and related symptoms.

The application discloses a kind of total glycosides of Paeonia lactiflora and non-steroidal anti-inflammatory drug composition in transdermal drug preparation application.In transdermal drug preparation the application advantage of this composition is in:(1) the active epidermal barrier and stratum corneum barrier of skin is the main obstacle of total glycosides of Paeonia lactiflora transdermal absorption.The non-steroidal anti-inflammatory drug in the composition can reversibly open the active epidermal barrier of skin, if it is used with the skin stratum corneum barrier of penetration enhancer and can significantly improve the transdermal penetration performance of total glycosides of Paeonia lactiflora in this transdermal drug preparation, it is a kind of with simple preparation process, easy industrial production, skin non-invasive characteristics can safely, efficiently improve the method for the transdermal penetration ability of total glycosides of Paeonia lactiflora;(2) total glycosides of Paeonia lactiflora and non-steroidal anti-inflammatory drug combination in transdermal drug preparation, in the curative effect of treating primary dysmenorrhea and rheumatoid arthritis disease has obvious synergistic effect, curative effect is excellent.

The invention discloses a solid-liquid two-phase anti-inflammatory essential oil microneedle as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing, medicine preparation processing and medicine delivery. The microneedle comprises a solid microneedle backing layer formed by hyaluronic acid and a solid-liquid two-phase needle body, wherein essential oil and a non-steroidal anti-inflammatory drug are wrapped in the needle body. The preparation method comprises the following steps: dissolving the non-steroidal anti-inflammatory drug in the essential oil to form an oil phase; mixing and emulsifying the oil phase and a hyaluronic acid aqueous solution to form an emulsion; and filling the emulsion into a microneedle mold, centrifuging, drying and demolding. According to the microneedle, the anti-inflammatory repair effect of the essential oil and the advantages of transdermal drug delivery of the microneedle are combined, micron-sized essential oil liquid drops are released in the skin, the essential oil is used as a drug carrier and a release regulator, efficient loading and slow release of the insoluble non-steroidal anti-inflammatory drug are achieved, the acting time of the drug on a focus part is remarkably prolonged, and the effect of the drug on the focus part is improved. The transdermal delivery efficiency and the treatment effect on inflammatory diseases such as osteoarthritis are improved.